TRICIDA INC (TCDA) Stock Price, Forecast & Analysis
NASDAQ:TCDA • US89610F1012
TCDA Key Statistics, Chart & Performance
The current stock price of TCDA is 0.108 USD. In the past month the price decreased by -34.62%. In the past year, price decreased by -98.91%.
TCDA Technical Analysis
TCDA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCDA. TCDA may be in some trouble as it scores bad on both profitability and health.
TCDA Financial Highlights
Over the last trailing twelve months TCDA reported a non-GAAP Earnings per Share(EPS) of -2.36. The EPS increased by 32.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TCDA Forecast & Estimates
8 analysts have analysed TCDA and the average price target is 19.72 USD. This implies a price increase of 18159.26% is expected in the next year compared to the current price of 0.108.
TCDA Ownership
TCDA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TCDA
Company Profile
Tricida, Inc. is a pharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 57 full-time employees. The company went IPO on 2018-06-28. TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. The company is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The firm's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.
Company Info
TRICIDA INC
7000 Shoreline Court, Suite 201
South San Francisco CALIFORNIA 94080 US
CEO: Gerrit Klaerner
Employees: 57
Phone: 14154297800.0
TRICIDA INC / TCDA FAQ
What does TRICIDA INC do?
Tricida, Inc. is a pharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 57 full-time employees. The company went IPO on 2018-06-28. TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. The company is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The firm's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.
What is the stock price of TRICIDA INC today?
The current stock price of TCDA is 0.108 USD. The price decreased by -10% in the last trading session.
What is the dividend status of TRICIDA INC?
TCDA does not pay a dividend.
What is the ChartMill rating of TRICIDA INC stock?
TCDA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of TRICIDA INC (TCDA)?
TRICIDA INC (TCDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.36).
Who owns TRICIDA INC?
You can find the ownership structure of TRICIDA INC (TCDA) on the Ownership tab.